TrialCancer2021

A phase 2a, single-arm, open-label study of tafasitamab, a humanized, Fc-modified, anti-CD19 antibody, in patients with relapsed/refractory B-precursor cell acute lymphoblastic leukemia.

Rebecca B Klisovic et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.